Navigation Links
Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Date:8/19/2007

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today revealed that recent experiments with its small-molecule MIF inhibitors showed oral efficacy in animal models. Based on these results, the Company announced that it is advancing one of these compounds into preclinical development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various infections and autoimmune disorders. Neutralization of MIF biological activity has been shown to have a protective effect against these diseases. CPSI has an extensive patent portfolio focused on MIF, covering various methods for neutralization, including small molecules. These compounds were recently shown to be effective in animal models of multiple sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State University in Columbus, OH. Dr. Satoskar stated: "The therapeutic efficacy of these compounds was impressive with no outward signs of toxicity. These findings indicate that small-molecule MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most difficult hurdle for a new therapy. We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to have a small molecule MIF inhibitor that is orally active. MIF is an important target in many diseases and an oral treatment is a definite advantage." Dr. Sielecki will present the MS and arthritis results at the annual American Chemical Society conference on August 22, 2007, in Boston, MA.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, visit to http://www.cytokinepharmasciences.com .


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)...  Genesis Healthcare Services has merged with Hospice Cloud, ... Bill Monast , President and CEO of Hospice ... Feltman , executives with Home Health Depot, Inc., the ... This acquisition helps Hospice Cloud maintain its position ... medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... Corp. (NYSE: NVRO), a global medical device company that is ... today reported financial results for the three months and full ... & Highlights: Achieved revenue of $228.5 million ... reported, over the prior year U.S. revenue of ... prior year International revenue of $55.2 million ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... ... ... Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he will ... the Management Committee when IFN was originally formed in 2002 where he was ultimately ... of the business plan. He became the first paid employee of IFN in ...
(Date:2/24/2017)... Lawn, NJ (PRWEB) , ... February 24, 2017 ... ... with robust marketing services, which specializes in thought leadership , media relations, ... marketing campaigns and services that will be powered through Act-On, an intuitive marketing ...
Breaking Medicine News(10 mins):